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Abstract
background—A 2007 national report identified North Carolina’s Edgecombe County as having 
among the highest breast cancer incidence and mortality rates nationally, motivating the initiation 
of a task force and other local efforts to address the problem. The goal of this study is to examine 
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county breast cancer characteristics before and after the report, including whether geographic 
variation may mask racial disparities in this majority African American community.
method—With guidance from community partners, breast cancer cases from 2000 to 2012 in 
Edgecombe, Nash, and Orange Counties (N = 2,641) were obtained from the North Carolina 
Central Cancer Registry. Bivariate and trend analyses of tumor and treatment characteristics were 
examined by county and race.
results—Women in Edgecombe and Nash Counties were diagnosed with more advanced stage, 
higher grade tumors. African Americans in Edgecombe and Nash Counties were diagnosed with 
advanced disease more often than African Americans in Orange County. Average time-to-
treatment was well within guideline recommendations. Incidence and mortality rates appear to 
have declined, with variation in measures of racial differences over time.
limitations—Changes in coding standards across the observation period required reliance on 
coarse measures that may partially mute useful findings.
conclusions—Racial disparities remain a concern in North Carolina; however, they appear to be 
less profound than in the 2007 national report. The portentous statistics in the report represent an 
all-time high, after which some, but not all, measures reflect positive change amidst ongoing local 
efforts to improve breast cancer knowledge and care.
Breast cancer is the most commonly diagnosed cancer in women and the second most 
common cause of cancer deaths, with 246,660 new cases and 40,450 deaths estimated for 
2016 in the United States [1]. From 2008 to 2012, 43,740 women were diagnosed in North 
Carolina and 6,357 died from breast cancer [2, 3].
Many factors influence breast cancer outcomes, including stage at diagnosis, tumor grade 
(aggressiveness), and hormone receptor status [4–6]. Tumor characteristics determine 
treatment options, which vary in effectiveness [7]. African American (AA) women are at 
disproportionate risk for poor outcomes for several reasons. Among them, AA women are 
more likely than Caucasian American (CA) women to be diagnosed with higher stage (more 
advanced) disease, higher grade tumors, and hormone receptor negative tumors, which have 
fewer treatment options [8–11]. Differing cultural norms and insufficient monetary or local 
health care resources decrease the likelihood of having a regular source of health care or 
being able to adhere to cancer screening guidelines, resulting in diagnostic and treatment 
delays [12–14]. These factors are particularly relevant for Edgecombe County, North 
Carolina, where 58% of residents are AA, median income is much lower than other areas of 
the state, and health care resources are limited as denoted by its designation as a Medically 
Underserved Area [15, 16].
In 2007, Susan G. Komen for the Cure, the nation’s most well-known breast cancer 
advocacy group, listed North Carolina’s Edgecombe County as having the 16th-worst breast 
cancer mortality rate in the nation, with 38% of women with breast cancer dying from the 
disease compared to 26% nationally [17]. The report sent shockwaves through the North 
Carolina cancer community and sparked several efforts to understand and address the factors 
responsible for these poor outcomes. Funded by the National Cancer Institute, the Carolina 
Community Network (CCN) is a regional cancer network program that aims to reduce 
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cancer disparities among AAs in 13 North Carolina counties, including Edgecombe County. 
In response to the Edgecombe community’s concern about the Komen report’s findings, 
CCN leveraged supplemental funding to examine the elevated rates together with a 
community advisory board (CAB).
The goal of this examination is to provide a contemporary understanding of breast cancer 
incidence and mortality rates following the release of the Komen report, including 
geographic differences in factors associated with breast cancer mortality and whether racial 
disparities may be masked by these geographic differences. We describe population breast 
cancer characteristics before and after the Komen report, and illustrate local community 
efforts (see Table 1) intended to address the disproportionate burden of breast cancer 
experienced in Edgecombe County.
Methods
Community Advisors
The use of CABs promotes understanding of local organizations and improves the relevance, 
integrity, and accountability of research efforts and their prospective positive impact in the 
community. CABs have been shown to be an effective approach to addressing disparities in 
health outcomes [18]. CAB members included 3 CCN community partners representing the 
local community, local health care providers, community-based public health organizations, 
and community support and development organizations. One member pioneered the 
formation of the volunteer Edgecombe County Breast Cancer Task Force that included 
community members, health care providers, and local organizations in response to the 
Komen report.
The CCN and CAB collaboratively identified the study questions and comparator counties. 
CCN team members independently performed all data management and analysis, including 
development of results and their primary interpretation. Meanwhile, CAB members 
articulated the community-based efforts and offered additional interpretation of results and 
discussion of implications for their community.
Comparison Counties
Two counties, Nash and Orange, were selected as comparators to Edgecombe County 
because they are proximal CCN area counties with similarities to Edgecombe. However, 
there were key differences between the counties. For example, Nash County is adjacent to 
Edgecombe but differs in race group composition (Nash: 55.9% CA, 37.2% AA; 
Edgecombe: 38.8% CA, 57.4% AA), and Orange County is more affluent with substantial 
local health care resources, including 2 academic medical centers with National Cancer 
Institute-designated cancer centers [19]. It was perceived that if racial inequities exist, they 
may be better seen in comparing Edgecombe to Nash; if resource and access issues exist, 
they may be seen in comparing Orange.
North Carolina Central Cancer Registry (NCCCR) data were obtained for 2,803 women 
living in Edgecombe, Nash, or Orange County and diagnosed with breast cancer between 
years 2000 and 2012. The sample was restricted to AA and CA women because limited 
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numbers from other minority populations precluded their examination while adhering to the 
data use agreement. To minimize bias, we examined analytic cases—those that were 
diagnosed and received most treatment at a North Carolina facility (N = 2,641; 94.2% of all 
cases)—and excluded those diagnosed at autopsy or treated primarily out of state.
Breast Cancer Characteristics
The study examined variables associated with breast cancer incidence and outcomes, such as 
age at diagnosis, race, tumor characteristics (including stage at diagnosis), and first course of 
therapy [4, 5]. Measures, including stage at diagnosis, tumor grade, and hormone receptor 
status, were selected because they are associated with differences in survival and may inform 
future research or interventions [6]. Summary stage at diagnosis was used because it was the 
most complete and consistent measure of tumor stage across the 13-year study period. 
Tumor receptor status includes estrogen-receptor (ER) and progesterone-receptor (PR) 
status; human epidermal growth factor receptor (HER2) status was not consistently reported 
during the study period and is not included. These tumor characteristics are primary 
determinants of relevant treatment options [7], which were analyzed as informed by 
consensus guidelines. For early-stage breast cancer, consensus guidelines recommend either 
breast conserving surgery (BCS) plus radiation therapy (RT) or mastectomy, which have 
equivalent survival, though BCS/RT is often preferred because it is less disfiguring and has 
lower morbidity [20]. Women who have BCS with no RT were examined because they have 
reduced survival compared to women who have BCS [21]. For more advanced disease, 
chemotherapy improves survival [22]; however, women with hormone receptor negative 
disease (“Triple-negative”) have fewer treatment options, contributing to comparatively 
worse survival. We examined number of days from diagnosis to treatment initiation since 
delays of 3 or more months are associated with worse survival [23].
County-level and state-level incidence rates and mortality rates are presented as reported by 
the NCCCR to promote consistency with official, previously-reported statistics [2, 3, 17]. 
Five-year rates reflect the sum of 5 years of incidence or mortality and are used to smooth 
out spurious fluctuation, are per 100,000 population, and are age-adjusted to the year 2000 
US Census.
Statistical Analysis
Subsets of time periods were examined to explore trends or changes over time as well as 
how the population experience may have differed before and after the Komen report. Chi-
square tests examined distributional differences in categorical data and excluded individuals 
with missing/unknown data. Two-sided t-tests were used for continuous variables. Analyses 
of small sample sizes were confirmed using Fisher’s exact test. All P-values are unadjusted 
and two-tailed. Because treatment schemas differ by stage at diagnosis, treatment data were 
analyzed by stage at diagnosis. Analysis examined receipt of mastectomy or BCS plus RT as 
markers for guideline-concordant care in the context of localized disease and, separately, 
regional disease. Limited sample size precluded examination of distant disease [24]. Time 
between diagnosis and treatment initiation was examined for all groups.
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Edgecombe County’s 2003 breast cancer incidence rate of 185.3/100,000 was featured in the 
2007 Komen report [17], which drew from NCCCR reports [25], but appears to be a peak, 
before and after which incidence rates were notably lower (see Figure 1). North Carolina’s 
2005 breast cancer mortality rate of 25.6/100,000 was also featured, after which it appears to 
be declining. Since that time, Edgecombe County has experienced a 16% decline, though 
with some volatility, while the other counties have experienced apparently less substantial 
changes.
Overall demographic and tumor characteristics are presented by county in Table 2 and relate 
to geographic differences in mortality. Women in Edgecombe and Nash Counties were more 
likely in 2007–2012 to be diagnosed with more advanced stage of disease compared to 
women in Orange County (P = .001, P = .013, respectively). Throughout the study 
observation period, they were also more likely than women in Orange County to be 
diagnosed with higher grade disease, though statistical significance varied. They were 
consistently much more likely to be diagnosed with hormone receptor negative disease 
compared to women in Orange County (P <0.001).
Demographic and tumor characteristics are further broken down by race in Table 3 and 
relate to whether geographic differences may mask racial disparities. The racial distribution 
of new breast cancer cases roughly paralleled overall population characteristics in each 
county, with AAs representing 54.9% of incident cases in Edgecombe County, 34.6% of 
cases in Nash County, and 12.6% of cases in Orange County in 2007–2012. CA women 
tended to be older at diagnosis compared to AA women, though statistical significance 
varied by county and time period. AA women tended to be diagnosed with more advanced 
disease compared to CA women, particularly in Edgecombe and Nash Counties, though in 
2007–2012 this was only statistically significant in Nash County (P = .018). In addition, AA 
women were consistently more likely than CA women to be diagnosed with higher grade 
disease. AA women were more likely to be hormone receptor negative than CAs in all 
counties and years, though the strength of this difference may be lessening over time.
Treatment characteristics are examined in Table 4. Among those with localized disease, AAs 
experienced greater time from diagnosis to treatment initiation in 2000–2006 in Nash (P = .
007) and Orange Counties (P = .081), though this difference of only several days was well 
within consensus guidelines and no longer statistically significant in 2007–2012. Treatment 
patterns were generally similar. Among women receiving BCS, AA BCS patients in 
Edgecombe County were less likely than AA BCS patients in Nash County to receive RT in 
2000–2006 (67% receiving RT vs 80%, P = .082). The proportion of early-stage Edgecombe 
County AA BCS patients receiving RT appeared to improve in the 2007–2012 time period 
(85% vs 67% previously, trend P = .090) and was no longer significantly different from 
other counties. AA BCS patients in Orange County were less likely than AA BCS patients in 
Nash County to receive RT in the more recent time period (73% with RT vs 90%, P = .039).
Among those with regional disease, racial differences in time from diagnosis to treatment 
were modest and only statistically significant in Orange County in 2007–2012 (P = .041). 
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AA women in Edgecombe and Nash Counties appeared to be more likely than CA women to 
have chemotherapy in the most recent time period (P = .025 for each). Small sample size 
precluded substantive analysis of those with distant disease.
Discussion
Cancer health disparities remain a concern in North Carolina in general, and in Edgecombe 
and Nash Counties specifically; however, these findings suggest that geographic and racial 
disparities in breast cancer in Edgecombe County are not as profound as suggested by the 
2007 Komen Report. Notably, the 2003 incidence rate of 185.3/100,000 presented in the 
Komen Report appears to be an all-time high for Edgecombe County. Since then, 
Edgecombe appears to have followed a trend more comparable to that seen in other counties, 
which generally reflects recent trends seen nationally [1]. The Komen Report spurred several 
efforts to increase community awareness, coordinate regional breast cancer resources, and 
build upon community-based efforts already underway. The declining mortality rate may in-
part reflect that these efforts have begun to bear fruit.
Among community efforts (see Table 1), a lay health advisor program—initiated in the early 
2000s based in local beauty shops and more recently enhanced through grant funding [26]—
has sought to overcome cultural barriers by providing information on breast cancer in 
general and increasing people’s awareness of breast cancer screening specifically, including 
by referring people to the health department and elsewhere for screening. Throughout the 
2000s, several other efforts were funded by agencies like the North Carolina Office of 
Minority Health and Health Disparities, the Susan G. Komen Foundation, and even the 
CCN, and the community was introduced to new levels of detail regarding breast cancer, 
including the existence of different disease subtypes and AA women’s differential 
susceptibility to more aggressive subtypes like hormone receptor negative disease. Of 
course, both the Komen Report itself and the activities of these community groups may have 
fueled local health care organizations’ more global discussions of affiliation or collaboration 
with major medical centers, which may in turn have contributed to accelerated adoption of 
treatment innovations or quality of care protocols; however, while there may be some 
association between these efforts and changes in outcomes, such a causal association cannot 
be firmly attributed. This said, the task force that formed following the Komen report 
continues to utilize cancer data to review community needs, available resources, and service 
access issues, and coordinate activities to address them. As an example, Edgecombe 
County’s Vidant Health, a member of the task force, has been addressing some of the 
identified gaps by leveraging the successes of the lay health advisor program and integrating 
previously-trained advisors into the health care system as cancer health navigators. However, 
the sustainability of such services is unclear, as the external grant funding that helped initiate 
the development of these many efforts has drawn to a close.
While some measures suggest there has been positive progress, other measures do not, 
suggesting there has not been a comprehensive or systematic shift in the profile of 
Edgecombe County’s breast cancer burden. Accordingly, the details regarding the specific 
cause, strength, and permanence of the changes in incidence and mortality remain unclear. 
For example, a traditional marker for a successful cancer screening program is when disease 
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is increasingly detected at an earlier, more treatable stage with associated longer survival. 
This analysis reveals that women in both Edgecombe and Nash counties remain more likely 
to be diagnosed with advanced disease compared to women in Orange County. While there 
is no statistically significant trend, Orange County appears to be consistently improving and 
diverging from the other 2 counties. There appears to be a positive shift in other tumor 
characteristics though, as tumors have tended to be lower grade and more likely to be 
hormone receptor positive over time. This less aggressive, more treatable disease may be 
playing a role with the improvement in mortality. Taken together, this shift in population 
tumor characteristics may actually partly reflect a demographic aberration that warrants 
further attention, as the population of these 2 counties is both shrinking and aging [16]. This 
may partly explain the slight trend toward less aggressive (grade) disease among residents, 
since breast cancer among older women is often a less aggressive phenotype [27].
Several measures of treatment characteristics are consistent across time, suggesting changes 
in access to treatment may not necessarily be the primary drivers of the apparent 
improvement in mortality. For example, while there were some geographic and racial 
differences in the time between diagnosis and treatment initiation, the differences were not 
substantial and all groups were well within consensus recommendations. This said, there 
appears to have been a notable change in quality of care vis-à-vis improvement in the 
guideline-concordant use of RT following surgery for those diagnosed with either local or 
regional disease. This was apparent in Edgecombe County overall and especially among AA 
women. For example, among AA women with early-stage disease, the proportion receiving 
BCS/RT increased from 67% in 2000–2006 to approximately 85% in 2007–2012. This 
change was similar among AA women with regional disease among whom BCS/RT 
increased from approximately 44% to approximately 71%. Nash and Orange Counties saw a 
less substantial improvement in this measure for these populations. This finding is 
particularly important for understanding changes in quality of care in Edgecombe County 
both overall and in the context of racial disparities, since a much greater proportion of the 
population is AA in Edgecombe (54%) and Nash (33%) compared to Orange (13%). An 
increase in RT use after surgery is expected to lead to an improvement in long-term overall 
survival for patients with localized and regional breast cancer [28–30], and the impact of 
these positive changes may only be beginning to be seen in the decline in mortality.
Among policy implications, programs to spur economic development and job (re)training in 
Edgecombe County may help. Economic development can translate to more jobs/
employment, which typically is associated with better insurance coverage and local health 
resources, which in turn can be associated with better access to cancer prevention/early 
detection and treatment. It may also help stabilize the apparent out-migration of younger 
residents, the full implications of which are unclear. Additional targeted funding from 
government or grant sources could help support some of the programs presented in Table 1, 
while additional research works to identify root causes of breast cancer incidence and 
mortality and effective interventions to resolve them.
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State tumor registry data are widely perceived as well-suited for characterizing patient and 
tumor characteristics at diagnosis and hospital-based treatment. Data on surgery are 
considered to be of highest quality, followed closely by radiation therapy, and more distantly 
by chemotherapy [24], which is almost exclusively delivered in the outpatient setting. 
Among study limitations, these factors and the limited sample size for patients with 
advanced disease inhibited the characterization of treatment for the chemotherapy 
population and require thoughtful interpretation. Notably, since chemotherapy data may be 
better reported for hospital-associated outpatient clinics compared with free-standing 
physician practices, apparent geographic variation in chemotherapy use may in part reflect 
infrastructure and reporting differences and not quality of care differences.
The American Joint Committee on Cancer (AJCC) TNM (tumor, node, and metastases) 
Staging System provides the contemporary criteria for disease characterization and treatment 
determination based on tumor characteristics and extent of disease. The more-precise TNM 
staging was not the standard throughout the study period, and completeness was limited and 
varied by county. The measure of summary stage (ie, local, regional, distant stage at 
diagnosis) was more complete and consistent; however, its coarseness—relative to more 
current staging systems with their more precise stage categories—may mute important yet 
subtle changes in outcomes, such as shifts in stage at diagnosis that may result from 
improved screening rates associated with nascent community screening programs. As they 
mature, the more fine-grained measures may yield more nuanced understanding and inform 
future efforts to improve treatment and outcomes.
For several reasons, including the impracticality of power calculations given the data source/
sample as well as the broad goals of the manuscript, we present the unadjusted P-values; 
only measures with highly significant P-values should be viewed most confidently.
Conclusion
These findings document the beginning of positive changes in outcomes amidst ongoing 
community efforts to address the disproportionate burden of breast cancer in Edgecombe 
County. These efforts originated through local community and academic partnerships and 
were supported by grants from foundations, the North Carolina Office of Minority Health 
and Health Disparities, and research programs such as the CCN [26]. Despite improvement 
among some measures in recent years, the apparent progress may be short-lived given the 
variation in findings among other measures and the declines in funding for community-
based health promotion and prevention. Going forward, additional targeted funding may 
support these community-identified needs for a more comprehensive knowledge of breast 
health and improvements in care that can yield lasting betterment in breast cancer outcomes. 
Future research should examine these issues and programs more specifically, with an eye 
toward identifying the root causes of the disproportionate breast cancer burden that are 
amenable to scientifically testable interventions. It is our hope that this study will inform 
such research and interventions.
Vines et al. Page 8














The Carolina Community Network is supported by the National Cancer Institute’s Center to Reduce Cancer Health 
Disparities through its Community Networks Program (U01 CA 114629) and Community Networks Program 
Centers (U54 CA 153602). We are grateful to Soundarya Radhakrishnan and the North Carolina Central Cancer 
Registry for their kind assistance with regard to data access and interpretation. We acknowledge with appreciation 
the efforts and contribution of Reuben Blackwell with Opportunities Industrialization Center, Inc. (OIC) in Rocky 
Mount, North Carolina.
References
1. American Cancer Society. Cancer Facts and Figures 2016. Atlanta, GA: American Cancer Society; 
2016. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-
cancer-facts-and-figures/2016/cancer-facts-and-figures-2016.pdf [Accessed August 9, 2017]
2. North Carolina Central Cancer Registry. 2008–2012 North Carolina Cancer Incidence Rates by Race 
and Ethnicity per 100,000 Population Age-Adjusted to the 2000 Census. Raleigh, NC: North 
Carolina Central Cancer Registry; 2016. http://www.schs.state.nc.us/schs/CCR/incidence/
2012/5yearRatesbyRaceEth_v3.pdf [Accessed August 9, 2017]
3. North Carolina Central Cancer Registry. 2008–2012 North Carolina Cancer Mortality Rates by Race 
and Ethnicity per 100,000 Population Age-Adjusted to the 2000 Census. Raleigh, NC: North 
Carolina Central Cancer Registry; 2014. http://www.schs.state.nc.us/schs/CCR/mort2012re.pdf 
[Accessed August 9, 2017]
4. Kushi LH, Kwan ML, Lee MM, Ambrosone CB. Lifestyle factors and survival in women with 
breast cancer. J Nutr. 2007; 137(1 Suppl):236S–242S. [PubMed: 17182833] 
5. Masood S. Prognostic/predictive factors in breast cancer. Clin Lab Med. 2005; 25(4):809–825. 
[PubMed: 16308094] 
6. Dawson SJ, Provenzano E, Caldas C. Triple negative breast cancers: clinical and prognostic 
implications. Eur J Cancer. 2009; 45(Suppl 1):27–40. [PubMed: 19775602] 
7. Polacek GN, Ramos MC, Ferrer RL. Breast cancer disparities and decision-making among U.S. 
women. Patient Educ and Couns. 2007; 65(2):158–165.
8. Chlebowski RT, Chen Z, Anderson GL, et al. Ethnicity and breast cancer: factors influencing 
differences in incidence and outcome. J Natl Cancer Inst. 2005; 97(6):439–48. [PubMed: 15770008] 
9. Dunn BK, Agurs-Collins T, Browne D, Lubet R, Johnson KA. Health disparities in breast cancer: 
biology meets socioeconomic status. Breast Cancer Res Treat. 2010; 121(2):281–292. [PubMed: 
20437200] 
10. Li CI, Malone KE, Daling JR. Differences in breast cancer hormone receptor status and histology 
by race and ethnicity among women 50 years of age and older. Cancer Epidemiol Biomarkers 
Prev. 2002; 11(7):601–607. [PubMed: 12101106] 
11. Millikan RC, Newman B, Tse CK, et al. Epidemiology of basal-like breast cancer. Breast Cancer 
Res Treat. 2008; 109(1):123–139. [PubMed: 17578664] 
12. Sassi F, Luft HS, Guadagnoli E. Reducing racial/ethnic disparities in female breast cancer: 
screening rates and stage at diagnosis. Am J Public Health. 2006; 96(12):2165–2172. [PubMed: 
17077392] 
13. Swan J, Breen N, Coates RJ, Rimer BK, Lee NC. Progress in cancer screening practices in the 
United States: results from the 2000 National Health Interview Survey. Cancer. 2003; 97(6):1528–
1540. [PubMed: 12627518] 
14. Bradley CJ, Given CW, Roberts C. Race, socioeconomic status, and breast cancer treatment and 
survival. J Natl Cancer Inst. 2002; 94(7):490–496. [PubMed: 11929949] 
15. Health Resources and Services Administration. HRSA website; Medically Under-served Areas and 
Populations. https://bhw.hrsa.gov/shortage-designation/muap. Updated October 2016 [Accessed 
August 9, 2017]
16. US Census Bureau. Quickfacts: Edgecombe County. North Carolina: US Census Bureau website; 
http://www.census.gov/quickfacts/table/POP060210/37065 [Accessed August 9, 2017]
Vines et al. Page 9













17. Susan G Komen for the Cure. Breast Cancer Mortality Report: Closing the Gaps in Eight 
Communities. Susan G Komen for the Cure; 2007. http://www.komennyc.org/pdfs/
ClosingTheGap-Mortality-Report-Narratives.pdf [Accessed October 30, 2017]
18. Newman SD, Andrews JO, Magwood GS, Jenkins C, Cox MJ, Williamson DC. Community 
advisory boards in community-based participatory research: a synthesis of best processes. Prev 
Chronic Dis. 
19. US Census Bureau. Census Data Quick Facts. US Census Bureau website; https://www.census.gov/
quickfacts/table/PST045216/00 [Accessed August 9, 2017]
20. NIH Consensus Conference. Treatment of early breast cancer. JAMA. 1991; 265(3):391–395. 
[PubMed: 1984541] 
21. Truong PT, Bernstein V, Lesperance M, Speers CH, Olivotto IA. Radiotherapy omission after 
breast-conserving surgery is associated with reduced breast cancer-specific survival in elderly 
women with breast cancer. Am J Surg. 2006; 191(6):749–755. [PubMed: 16720143] 
22. Briest S, Stearns V. Chemotherapeutic strategies for advanced breast cancer. Oncology (Williston 
Park). 2007; 21(11):1325–1335. [PubMed: 18080617] 
23. Richards MA, Westcombe AM, Love SB, Littlejohns P, Ramirez AJ. Influence of delay on survival 
in patients with breast cancer: A systematic review. Lancet. 1999; 353(9159):1119–1126. 
[PubMed: 10209974] 
24. Malin JL, Kahn KL, Adams J, Kwan L, Laouri M, Ganz PA. Validity of cancer registry data for 
measuring the quality of breast cancer care. J Natl Cancer Inst. 2002; 94(11):835–844. [PubMed: 
12048271] 
25. North Carolina Central Cancer Registry. Statistics and reports. North Carolina: Health Statistics 
website; http://www.schs.state.nc.us/data/cancer.cfm. Updated April 3, 2017 [Accessed August 9, 
2017]
26. Teal R, Moore AA, Long DG, Vines AI, Leeman J. A community-academic partnership to plan and 
implement an evidence-based lay health advisor program for promoting breast cancer screening. J 
Health Care Poor Underserved. 2012; 23(2 Suppl):109–120. [PubMed: 22643559] 
27. Anders CK, Johnson R, Litton J, Phillips M, Bleyer A. Breast cancer before age 40 years. Semin 
Oncol. 2009; 36(3):237–49. [PubMed: 19460581] 
28. Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of 
surgery for early breast cancer on local recurrence and 15-year survival: an overview of the 
randomised trials. Lancet. 2005; 366(9503):2087–2106. [PubMed: 16360786] 
29. Darby S, McGale P, et al. Early Breast Cancer Trialists’ Collaborative Group. Effect of 
radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer 
death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 
2011; 378(9804):1707–1716. [PubMed: 22019144] 
30. McGale P, Taylor C, et al. Early Breast Cancer Trialists’ Collaborative Group. Effect of 
radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast 
cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. 
Lancet. 2014; 383(9935):2127–2135. [PubMed: 24656685] 
Vines et al. Page 10













figure 1. Age-Adjusted 5-Year Incidence and Mortality Rates* for Breast Cancer, All Races and 
Ages
*Rates are per 100,000 population and age adjusted to the year 2000 US Census. Rates 
reflect 5 years of incidence or mortality (eg, 2012 incidence rates reflect the total incidence 
for years 2008–2012).
Note. Highlighted incidence and mortality statistics are those presented in the 2007 Komen 
Report.
Source. North Carolina Central Cancer Registry.
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TABLE 1
Timeline: Susan G. Komen for the Cure Breast Cancer Report and Edgecombe County Community Response
Founded 1969 Opportunities Industrialization Center, Inc. (OIC) in Rocky Mount, North Carolina provides comprehensive employment, 
training, business, and health services to strengthen the communities they serve. OIC has a mobile health unit, community 
education center, and a federally qualified health center.
Founded 1974 Rural Health Group, Inc. (RHG) in northeastern North Carolina (Halifax and Northampton counties) is a nonprofit, 
federally qualified community health center providing primary care, dental care, and other health-related services for the 
underserved. The RHG Community-based Outreach Program trained and coordinated breast cancer lay health advisors.
Founded 1999 Crossworks, Inc. is a faith-based nonprofit that provides health and nutrition education to fight chronic disease in Nash, 
Edgecombe, and the surrounding area.
2004 Creation of the UNC Center for Community Research, a community-based research center located in the Area L Area 
Health Education Center (AHEC), which targeted several counties. The goal was to reduce health disparities through 
community-academic partnerships. Crossworks, RHG, and OIC were influential community leaders and research partners 
already addressing health concerns in the community.
2005 National Cancer Institute Center to Reduce Cancer Health Disparities awarded infrastructure funds to UNC-Chapel Hill, 
establishing the Carolina Community Network (CCN). CCN used the infrastructure of the UNC Center for Community 
Research to target and address breast, colorectal, and prostate cancers in several counties.
2006 Initiation of CCN Community Grants Program. Crossworks and RHG received community grants from the CCN to address 
cancer disparities in Edgecombe county.
2007 Susan G. Komen for the Cure released report
September 2007 Breast Cancer Summit, Heritage Hospital, Tarboro, North Carolina (Now Vidant Edgecombe Hospital)
November 2007 Edgecombe County Breast Cancer Taskforce (ECBCT) created and first official meeting held
2007 Crossworks initiated Breaking Free Breast Cancer Lay Health Advisor Program. Received funding from the Susan G. 
Komen Foundation and North Carolina Office of Minority Health and Health Disparities Health and Wellness Program.
2008 ECBCT obtained $135,000 funding from Susan G. Komen for the Cure
May 2008 ECBCT hired Project Manager
2008–2009 Community Health Assessment for breast cancer with East Carolina University; recommendations include lay health 
advisor and patient navigation programs
August 2009 Patient navigator hired at Heritage Hospital
2008–2010 UNC-Chapel Hill provided Breast Cancer Screening Program train-the-trainer to 6 ECBCT trainers
2009–2010 Extensive Mammography Campaign
2010 Obtained $68,000 funding from Susan G. Komen for the Cure
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